Industry Veteran With More Than 25 Years Experience Will Lead Development and European Commercialization and Growth

SAN DIEGO, CA--(Marketwired - Jun 27, 2013) - Genelux Corporation, a clinical-stage biopharmaceutical company that develops vaccinia virus-based cancer therapeutics and diagnostics, today announced its Board of Directors has appointed Stefan M. Manth, MD, to lead Genelux Europe, as President and Chief Executive Officer effective July 1, 2013, based in Basel, Switzerland.

"The appointment of Dr. Manth to lead Genelux Corporation's European operations is a critical part of achieving our company's next phase of growth by managing our overseas activities to develop and commercialize our lead cancer therapy, GL-ONC1, and vaccinia virus-based diagnostics," said Dr. Aladar Szalay, Founder, Chairman and CEO. "Dr. Manth brings more than two decades of experience managing corporate strategy and pharmaceutical clinical and commercial product development, particularly in oncology, both globally, and on multiple local market levels."

Dr. Manth's medical and pharmaceutical management experience spans across a broad range of functions including commercialization, clinical development, strategic marketing, as well as business and corporate strategy management. From 1990 until 2011, Dr. Manth served at Hoffmann La Roche, most recently at the corporation's interface of Pharma and Diagnostics, to design and implement a joint personalized medicine strategy. Prior to this, Dr. Manth was Senior Vice President at Chugai Pharmaceuticals (a member of the Roche group) in Tokyo, Japan, where he effectively directed major corporate and operational change programs. From 2003 to 2005, Dr. Manth was Roche's Business Director Oncology with global responsibility for the design and execution of Roche's long-term oncology business strategy, and directing the worldwide development and launches of products like Tarceva and Avastin and major line-extensions to brands including Xeloda, Mabthera, and others.

Since leaving Roche in 2011, Dr. Manth has served as Chairman for Mucovax, a German startup biotechnology company, and on the Scientific and Strategic Advisory Board at Mologen AG. Dr. Manth received his medical training (MD and internship) at the Freie Universitaet, Berlin, and was awarded the title "Dr. med." upon completion of a thesis in experimental cardiac surgery. He holds an INSEAD MBA (Fontainebleu, France).

About Genelux Corporation

Headquartered in San Diego, California, Genelux Corporation is a privately held, clinical stage biopharmaceutical company dedicated to fundamentally changing the way in which cancer is diagnosed and treated. The company has developed a proprietary oncolytic vaccinia virus-based technology platform that can be engineered to insert specific therapeutic genes for delivery and amplification of anti-cancer proteins and RNA into cancer cells without harming healthy cells. This platform includes a green fluorescent protein (GFP) as a bioluminescent diagnostic. The company is also incorporating advanced diagnostic deep-tissue imaging technologies into its viral platform to enable highly specific visualization of tumors and circulating cancer cells. GL-ONC1 (http://www.genelux.com/gl-onc1/gl-onc1/), the company's lead oncology product candidate, is an attenuated vaccinia virus (Lister strain) that is currently under evaluation in multiple human clinical trials in the US and Europe. For more information please visit http://www.genelux.com.

Genelux Forward Looking Statement

Statements made about Genelux Corporation, other than statements of historical fact, reflect Management's current beliefs and assumptions founded on the data and information currently available to us. Statements of the company's progress, results, timing of pre-clinical and clinical trials and projections for product pipelines are examples of forward-looking statements. By definition, such undertakings involve risks, uncertainties and assumptions, and are subject to a number of such factors that could cause actual results to differ substantially from statements made, including but not limited to: risks associated with the success of clinical trials, research and development programs, regulatory approval processes for clinical trials, competitive technologies and products, patents, inception and/or continuation of corporate and other strategic partnerships and the need for additional funding or financing.